Ajanta Pharma Ltd Share Price
As on 13 June 2026 at 01:08 IST
Ajanta Pharmaceuticals Ltd Q1 FY25 Results:
Profit after tax for the period declined 4% to ₹255 crores in Q1 FY26, from ₹246 crores in Q1 FY25. Total income for the quarter increased 13.5% year-on-year to ₹1329 crores from ₹1171 crores.
About Ajanta Pharma Ltd
Ajanta Pharmaceuticals Ltd. was established in 1973. Headquartered in Mumbai, India, the company has grown into a prominent player in the pharmaceutical industry. It specializes in developing, manufacturing, and marketing pharmaceutical formulations across various therapeutic segments. This includes cardiology, dermatology, ophthalmology, and pain management. The company is recognized for its innovative approach. This has helped it secure leadership positions in multiple molecules and therapeutic areas. Ajanta Pharmaceuticals is not explicitly labelled as the top stock in its sector. However, its significant market presence and growth trajectory reflect its importance in the industry. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
2.58%
Over 6 Months
18.56%
Over 1 Year
18.76%
Over 3 Years
118.50%
Ajanta Pharma Ltd Summary
Close ₹3,143.40
Open ₹3,075.40
High ₹3,158.40
Low ₹3,061.80
Volume 1,92,433
Net Turnover (in Cr) ₹59.97
52Wk High ₹3,314.90
52Wk Low ₹2,329.90
52Wk High / Low
2,329.90
3,314.90
Ajanta Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹39,272.26
EPS (TTM) 75.78
Book Value (BV) 338.05
Div. Yield 0.89 %
P/E (TTM) 41.44
Price/Book Value 9.29
Delivery % 48.13 %
Face Value 2
Key Ratios
PE Ratio 35.80
PB Ratio 9.05
EV to Sales 7.56
PEG Ratio 2.47
ROA 24.52
ROE 26.05
Debt-Equity 0.01
Net Profit Margin 21.21
Operating Profit Margin 30.65
Ajanta Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,742.60 | 4,293.31 | 3,841.28 | 3,456.67 | 2,915.67 |
| Total Expenses | 3,553.44 | 3,179.38 | 3,096.03 | 2,547.19 | 2,015.49 |
| Profit Before Tax | 1,189.16 | 1,113.93 | 745.25 | 909.48 | 900.18 |
| Profit After Tax | 920.39 | 816.17 | 587.98 | 712.68 | 653.87 |
| Operating Profit After Depreciation | 1,209.89 | 1,121.14 | 751.09 | 919.68 | 908.45 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,762.02 | 1,479.19 | 1,496.44 | 1,503.58 | 1,532.21 |
| Total Non Current Assets | 2,171.92 | 1,907.47 | 1,845.02 | 1,791.12 | 1,751.13 |
| Total Current Assets | 2,843.03 | 2,730.92 | 2,834 | 2,264.46 | 2,027.59 |
| Total Assets | 5,014.95 | 4,638.39 | 4,679.02 | 4,055.58 | 3,778.72 |
| Total Shareholder's Fund | 3,790.29 | 3,567.36 | 3,387.99 | 3,264.34 | 2,995.63 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,157.23 | 785.07 | 792.11 | 561.71 | 576.31 |
| Net Cash Used In Investing Activities | -376.52 | 65.39 | -559.60 | -74.10 | -282.38 |
| Net Cash Used In Financing Activities | -733.41 | -1,051.06 | -108.20 | -459.71 | -318.29 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,441.91 | 4,087.60 | 3,544.02 | 3,280.37 | 2,822.16 |
| Total Expenses | 3,261.85 | 2,990.65 | 2,844.17 | 2,379.83 | 1,920.07 |
| Profit Before Tax | 1,180.06 | 1,096.95 | 699.85 | 900.54 | 902.09 |
| Profit After Tax | 916.89 | 807.24 | 558.72 | 719.86 | 675.64 |
| Operating Profit After Depreciation | 1,184.66 | 1,103.75 | 705.08 | 909.66 | 908.99 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,741.96 | 1,464.89 | 1,484.01 | 1,483.91 | 1,509.89 |
| Total Non Current Assets | 1,978.19 | 1,775.77 | 1,753.60 | 1,723.48 | 1,695.85 |
| Total Current Assets | 2,576.06 | 2,441.67 | 2,551.19 | 2,057.01 | 1,836.21 |
| Total Assets | 4,554.25 | 4,217.44 | 4,304.79 | 3,780.49 | 3,532.06 |
| Total Shareholder's Fund | 3,625.31 | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,053.80 | 735.35 | 736.29 | 542.34 | 466.99 |
| Net Cash Used In Investing Activities | -349.60 | 105.02 | -501.31 | -66.04 | -162.68 |
| Net Cash Used In Financing Activities | -715.71 | -1,047.70 | -105.12 | -457.30 | -268.90 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,421.64 | 1,374.84 | 1,353.73 | 1,302.65 | 1,170.41 |
| Total Expenses | 1,088.23 | 992.60 | 1,025.90 | 951.30 | 873.26 |
| Profit Before Tax | 347.11 | 358.60 | 340.81 | 331.13 | 269.41 |
| Profit After Tax | 266.70 | 273.77 | 260.19 | 255.34 | 225.26 |
| Operating Profit after Depreciation | 394.84 | 407.21 | 387.17 | 377.68 | 315.26 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,210.53 | 1,206.59 | 1,220.24 | 1,208.56 | 1,013.94 |
| Total Expenses | 972.48 | 865.64 | 930.65 | 879.16 | 764.29 |
| Profit Before Tax | 257.61 | 322.46 | 321.97 | 328.99 | 228.15 |
| Profit After Tax | 197.28 | 245.04 | 249.53 | 254.97 | 193.43 |
| Operating Profit after Depreciation | 301.03 | 366.71 | 364.62 | 370.03 | 267.58 |
Ajanta Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 3,084
S2 3,024.60
S3 2,987.40
Pivot 3,121.20
R1 3,180.60
R2 3,217.80
R3 3,277.20
Moving Average
20 SMA 3,068.67
50 SMA 2,941.75
100 SMA 2,911.20
200 SMA 2,739.89
Ajanta Pharma Ltd Corporate Actions
Ajanta Pharma Ltd
₹28.0/Share
Announcement Date 10 Nov 2025
Record Date 10 Nov 2025
Div Yield 1400%
Ajanta Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Ajanta Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 3.21% |
| Kotak Small Cap Fund | 1.88% |
| UTI-Mid Cap Fund | 1.85% |
| UTI-Flexi Cap Fund | 1.76% |
| Canara Robeco Small Cap Fund | 1.64% |
Ajanta Pharma Ltd News
Ajanta Pharma Ltd gains for third straight session
Ajanta Pharma Ltd is quoting at Rs 2993.7, up 1.56% on the day as on 12:49 IST on the NSE. The stock is up 16.43% in last one year as compared to a 6.52% jump in NIFTY and a 12.16% jump in the Nifty Pharma index.
05 Jun 2026, 01:05 pm
Ajanta Pharma Ltd spurts 1.08%, rises for third straight session
Ajanta Pharma Ltd is quoting at Rs 3125, up 1.08% on the day as on 12:49 IST on the NSE. The stock is up 20.83% in last one year as compared to a 4.86% gain in NIFTY and a 11.37% gain in the Nifty Pharma index.
13 May 2026, 01:05 pm
Ajanta Pharma rises after Q4 PAT climbs 18% YoY
Ajanta Pharma rose 3.49% to Rs 3,002.20 after the pharmaceutical company reported healthy Q4 FY26 earnings, driven by steady performance across branded markets.
06 May 2026, 10:05 am
Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant
Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.
22 Apr 2026, 10:06 am
Ajanta Pharma's Paithan unit concludes USFDA inspection
With 5 observations under Form - 483
22 Apr 2026, 09:22 am
Ajanta Pharma Ltd Stock Analysis
- Annual revenue for Ajanta Pharma Ltd increased by 8.67% to ₹4,441.91 crore in FY 2025 from ₹4,087.60 crore in FY 2024.
- Annual Net Profit for Ajanta Pharma Ltd increased by 13.58% to ₹916.89 crore in FY 2025 from ₹807.24 crore in FY 2024.
- Promoter Shareholding in Ajanta Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 66.25% in December 2025 to 66.25% in March 2026.
- Ajanta Pharma Ltd delivered a 1-year return of 18.76% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Ajanta Pharma Ltd share price moved up by 0.04% from its previous close of INR ₹3,143.40. The latest Ajanta Pharma Ltd share price is INR ₹3,144.70.
- Ajanta Pharma Ltd share price today has been at a low of 3,116.30 and a high of 3,178.90. Over the past 52 weeks, the Ajanta Pharma Ltd share price has seen a low of 2,329.90 and a high of 3,314.90.
About Ajanta Pharma Ltd
Ajanta Pharmaceuticals Ltd. was established in the year 1973. Headquartered in Mumbai, India, the company has grown into a prominent player in the pharmaceutical industry. It specialises in developing, manufacturing, and marketing pharmaceutical formulations across various therapeutic segments. This includes cardiology, dermatology, ophthalmology, and pain management.
Mr. Yogesh Agrawal (Managing Director) owns 14.47% of the company’s equity. Rajesh M Agrawal (Joint Managing Director) also owns a 14.47% stake in the company. Under the leadership of the Agrawal family, Ajanta Pharma has established a strong reputation for producing high-quality medicines. The company has expanded its reach to over 30 countries across Africa, South East Asia, West Asia, and the CIS region. Apart from the Agrawal family, some managerial promoters have contributed to the company’s success. They are
It is not explicitly labelled as the top stock in its sector. However, Ajanta Pharma’s significant market presence and growth trajectory reflect its importance in the pharmaceutical industry. The company’s registered office is located in Kandivali (West), Mumbai. Meanwhile, its registrars are based at L.B.S. Marg, Vikhroli.
Ajanta Pharma’s focus on quality and strategic expansion has positioned it as a key player in the pharmaceutical sector. As the company continues to grow and penetrate new markets, it remains dedicated to its mission of providing high-quality, affordable medicines to patients worldwide.
Ajanta Pharma places a strong emphasis on research and development (R&D). The company invests significantly in its R&D facilities, which are equipped with the latest technology. These facilities are staffed by a team of highly skilled scientists and researchers. This commitment to R&D enables Ajanta Pharma to stay ahead of the curve in developing new formulations and improving existing ones. The company’s R&D efforts are focused on creating value-added products that meet the needs of patients and healthcare providers.
One of the key factors behind Ajanta Pharma’s success in new product development is its deep understanding of market needs. The company conducts extensive market research to identify gaps in areas where new treatments are needed. This approach ensures that the products developed by Ajanta Pharma are relevant to real-world health issues.
Quality is at the core of Ajanta Pharma’s product development process. The company adheres to stringent quality control measures at every stage of production, from raw material sourcing to final product packaging. This focus on quality ensures that the products are safe, effective, and meet international standards. Ajanta Pharma’s commitment to quality has earned it a strong reputation in the pharmaceutical industry.
Ajanta Pharma has also leveraged strategic partnerships and collaborations. This is to enhance its product development capabilities. The company has partnered with leading research institutions and other pharmaceutical companies. This allows it to access new technologies and expertise that complement its own capabilities. As a result, these collaborations have enabled Ajanta Pharma to accelerate the development of new products.
Ajanta Pharma’s diverse product portfolio is another testament to its leadership in new product development. It offers diverse products across various therapeutic segments, including cardiology and pain management. This diversity allows the company to cater to a broad spectrum of healthcare needs. It also allows Ajanta Pharma to reduce its dependence on any single product or market.
Navigating the complex regulatory landscape is a critical aspect of new product development in the pharmaceutical industry. Ajanta Pharma has a dedicated regulatory affairs team. They ensure all products comply with the regulatory requirements of different markets. This approach to regulatory compliance helps the company avoid delays in product launches. It also ensures that its products are approved for use in multiple countries.
Ajanta Pharma’s customer-centric approach is integral to its new product development strategy. The company seeks feedback from healthcare professionals and patients to understand their preferences. This feedback is then incorporated into the product development process to create user-friendly and effective solutions. Ajanta Pharma ensures that its products are well-received in the market by prioritising the needs of its customers.
Ajanta Pharma’s leadership in new product development is a result of its strategic focus on innovation, quality, and market needs. As Ajanta Pharma continues to grow and expand its reach, it remains dedicated to developing new and effective medications that improve the health and well-being of patients around the world.
Mr. Yogesh Agrawal (Managing Director) owns 14.47% of the company’s equity. Rajesh M Agrawal (Joint Managing Director) also owns a 14.47% stake in the company. Under the leadership of the Agrawal family, Ajanta Pharma has established a strong reputation for producing high-quality medicines. The company has expanded its reach to over 30 countries across Africa, South East Asia, West Asia, and the CIS region. Apart from the Agrawal family, some managerial promoters have contributed to the company’s success. They are
- K H Viswanathan
- Anjana Grewal
- Prabhakar R Dalal
- Chandrakant M Khetan
It is not explicitly labelled as the top stock in its sector. However, Ajanta Pharma’s significant market presence and growth trajectory reflect its importance in the pharmaceutical industry. The company’s registered office is located in Kandivali (West), Mumbai. Meanwhile, its registrars are based at L.B.S. Marg, Vikhroli.
Ajanta Pharma’s focus on quality and strategic expansion has positioned it as a key player in the pharmaceutical sector. As the company continues to grow and penetrate new markets, it remains dedicated to its mission of providing high-quality, affordable medicines to patients worldwide.
How Ajanta Pharma Leads in New Product Development
Ajanta Pharma’s leadership in new product development is a result of its strategic focus on innovation, quality, and market needs. Established in 1973, the company has grown to become a significant player in the pharmaceutical industry. It is known for its ability to introduce new and effective medications across various therapeutic segments.Ajanta Pharma places a strong emphasis on research and development (R&D). The company invests significantly in its R&D facilities, which are equipped with the latest technology. These facilities are staffed by a team of highly skilled scientists and researchers. This commitment to R&D enables Ajanta Pharma to stay ahead of the curve in developing new formulations and improving existing ones. The company’s R&D efforts are focused on creating value-added products that meet the needs of patients and healthcare providers.
One of the key factors behind Ajanta Pharma’s success in new product development is its deep understanding of market needs. The company conducts extensive market research to identify gaps in areas where new treatments are needed. This approach ensures that the products developed by Ajanta Pharma are relevant to real-world health issues.
Quality is at the core of Ajanta Pharma’s product development process. The company adheres to stringent quality control measures at every stage of production, from raw material sourcing to final product packaging. This focus on quality ensures that the products are safe, effective, and meet international standards. Ajanta Pharma’s commitment to quality has earned it a strong reputation in the pharmaceutical industry.
Ajanta Pharma has also leveraged strategic partnerships and collaborations. This is to enhance its product development capabilities. The company has partnered with leading research institutions and other pharmaceutical companies. This allows it to access new technologies and expertise that complement its own capabilities. As a result, these collaborations have enabled Ajanta Pharma to accelerate the development of new products.
Ajanta Pharma’s diverse product portfolio is another testament to its leadership in new product development. It offers diverse products across various therapeutic segments, including cardiology and pain management. This diversity allows the company to cater to a broad spectrum of healthcare needs. It also allows Ajanta Pharma to reduce its dependence on any single product or market.
Navigating the complex regulatory landscape is a critical aspect of new product development in the pharmaceutical industry. Ajanta Pharma has a dedicated regulatory affairs team. They ensure all products comply with the regulatory requirements of different markets. This approach to regulatory compliance helps the company avoid delays in product launches. It also ensures that its products are approved for use in multiple countries.
Ajanta Pharma’s customer-centric approach is integral to its new product development strategy. The company seeks feedback from healthcare professionals and patients to understand their preferences. This feedback is then incorporated into the product development process to create user-friendly and effective solutions. Ajanta Pharma ensures that its products are well-received in the market by prioritising the needs of its customers.
Ajanta Pharma’s leadership in new product development is a result of its strategic focus on innovation, quality, and market needs. As Ajanta Pharma continues to grow and expand its reach, it remains dedicated to developing new and effective medications that improve the health and well-being of patients around the world.
FAQ’s
What is the share price of Ajanta Pharma Ltd today?
Ajanta Pharma Ltd share price as on 12 Jun 2026 is ₹ 3144.7
What is the Market Cap of Ajanta Pharma Ltd?
The market cap of Ajanta Pharma Ltd stock is ₹39,272.26 Cr.
What is the PE Ratio of Ajanta Pharma Ltd?
The Price to Earnings (P/E) Ratio of Ajanta Pharma Ltd is 35.80
What is the PB Ratio of Ajanta Pharma Ltd?
The Price to Book (P/B) Ratio of Ajanta Pharma Ltd is 9.05
What is the 52 week high of Ajanta Pharma Ltd Share Price?
The 52 week high of Ajanta Pharma Ltd share price stands at ₹3,314.90
What is the 52 week low of Ajanta Pharma Ltd Share Price?
The 52 week low of Ajanta Pharma Ltd share price stands at ₹2,329.90
How can I buy shares of Ajanta Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Ajanta Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
